Necroptotic Neurons is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Necroptosis is a programmed form of necrotic cell death mediated by RIPK1, RIPK3, and MLKL. It contributes to neurodegeneration in stroke, traumatic brain injury, and potentially in Alzheimer's and Parkinson's diseases.
This page provides comprehensive information about the subject's role in neurodegenerative diseases. The subject participates in various molecular pathways and cellular processes relevant to Alzheimer's disease, Parkinson's disease, and related conditions.
- TNF-α stimulation
- Fas ligand
- TLR activation
- Viral infections
- RIPK1: Kinase activation
- RIPK3: Phosphorylation and activation
- MLKL: Executioner phosphorylation
- MLKL oligomerization
- Membrane translocation
- Pore formation
- Cell lysis
- Aβ-induced necroptosis
- Tau-mediated toxicity
- Chronic inflammation
- Synaptic loss
- α-Synuclein toxicity
- Mitochondrial dysfunction
- Neuroinflammation
- Dopaminergic loss
- Ischemic injury
- Traumatic injury
- Excitotoxicity component
- Cytoplasmic swelling
- Organelle swelling
- Membrane rupture
- No nuclear fragmentation
- RIPK1/3 activation
- MLKL phosphorylation
- Cytokine release
- DAMPs release
- Necrostatin-1 (RIPK1)
- GSK'872 (RIPK3)
- Small molecule inhibitors
- MLKL inhibitors
- Anti-inflammatory agents
- Pre-conditioning
- Anti-death pathways
- Cellular energy support
- TNF-α + z-VAD
- Smac mimetics
- FAS ligand
- CRISPR activation
- Necrostatin-1
- GSK'872
- RIPK1 inhibitors
- MLKL inhibitors
- Circulating RIPK3
- MLKL fragments
- Inflammatory cytokines
- PET tracers (under development)
- MRI changes
- Molecular imaging
The study of Necroptotic Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Degterev et al., Chemical inhibitor of nonapoptotic cell death (2005)
- Caccamo et al., Necroptosis in AD and PD (2017)
- Liu et al., Necroptosis in neurodegeneration (2020)
- Kaiser et al., Targeting necroptosis (2021)